Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Cancers|April 12, 2022
Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived ExplantsMargaret M Centenera, Andrew D Vincent, Max Moldovan, et al.
Frontiers in Molecular Biosciences|February 6, 2023
A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancerSung-Young Shin, Margaret M Centenera, Joshua T Hodgson, et al.
Endocrine-Related Cancer|July 19, 2015
Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanismsMargaret M Centenera, Sarah L Carter, Joanna L Gillis, et al.
Oncotarget|May 16, 2013
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitorsJoanna L Gillis, Luke A Selth, Margaret M Centenera, et al.
Nature Communications|May 30, 2013
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancerPreethi Ravindranathan, Tae-Kyung Lee, Lin Yang, et al.
The Prostate|August 17, 2016
A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock ResponseHeather K Armstrong, Yen Chin Koay, Swati Irani, et al.
Molecular Cancer Therapeutics|August 13, 2017
The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate CancerLinh N K Tran, Ganessan Kichenadasse, Lisa M Butler, et al.
Molecular & Cellular Proteomics : MCP|April 11, 2018
Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor ExplantsElizabeth V Nguyen, Margaret M Centenera, Max Moldovan, et al.
BMC Cancer|February 25, 2016
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptorSarah L Carter, Sarah Louise Carter, Margaret M Centenera, et al.
BMJ Open|January 29, 2020
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)Tahlia Scheinberg, James Kench, Martin Stockler, et al.
Pageof 5